W. Schmidt

发表

THE GENERATION OF TUMOR VACCINES BY ADENOVIRUS ENHANCED TRANSFERRINFECTION OF CYTOKINE GENES INTO TUMOR CELLS

K. Zatloukal, E. Wagner, G. Maass, 1994 .

Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines.

W. Schmidt, M. Buschle, F. Mattner, 2002, Vaccine.

Granulocyte-Macrophage Colony-Stimulating Factor-Based Melanoma Cell Vaccines Immunize Syngeneic and Allogeneic Recipients via Host Dendritic Cells 1

H. Schild, P. Steinlein, W. Schmidt, 2003, The Journal of Immunology.

Methodological Aspects of the Phase II Study AFF006 Evaluating Amyloid-beta -Targeting Vaccine AFFITOPE® AD02 in Early Alzheimer's Disease - Prospective Use of Novel Composite Scales.

B. Dubois, S. Hendrix, W. Schmidt, 2015, The journal of prevention of Alzheimer's disease.

Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy

E. Masliah, E. Rockenstein, W. Schmidt, 2015, Molecular Neurodegeneration.

Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management

W. Schmidt, F. Mattner, S. Brunner, 2014, PloS one.

AFFITOME® technology in neurodegenerative diseases: The doubling advantage

W. Schmidt, F. Mattner, M. Mandler, 2010, Human vaccines.

Development of AFFITOPE vaccines for Alzheimer’s disease (AD) — From concept to clinical testing

W. Schmidt, F. Mattner, W. Zauner, 2009 .

Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity.

T. Luger, W. Schmidt, C. Curiel-Lewandrowski, 1999, Journal of immunology.

Granulocyte-Macrophage Colony-Stimulating Factor-Based Melanoma Cell Vaccines Immunize Syngeneic and Allogeneic Recipients via Host Dendritic Cells

H. Schild, W. Schmidt, A. Schneeberger, 2003 .

CellsAllogeneic Recipients via Host Dendritic Cell Vaccines Immunize Syngeneic and Colony-Stimulating Factor-Based Melanoma Granulocyte-Macrophage

H. Schild, W. Schmidt, R. Kutil, 2003 .

Somatic gene therapy for cancer: the utility of transferrinfection in generating 'tumor vaccines'.

K. Zatloukal, M. Cotten, E. Wagner, 1993, Gene.

Induction of Specific Immune Responses by Polycation-Based Vaccines1

S. Wagner, W. Schmidt, M. Buschle, 2002, The Journal of Immunology.

Capacity Enhances Their In Vivo Antigen-Presenting Colony-Stimulating Factor Gene Potently Granulocyte-Macrophage Marrow-Derived Dendritic Cells with the Transfection of Immature Murine Bone

T. Luger, W. Schmidt, C. Curiel-Lewandrowski, 1999 .

Transloading of tumor antigen-derived peptides into antigen-presenting cells.

K. Mechtler, W. Schmidt, M. Buschle, 1997, Proceedings of the National Academy of Sciences of the United States of America.

The tumorigenicity of IL-2 gene-transfected murine M-3D melanoma cells is determined by the magnitude and quality of the host defense reaction: NK cells play a major role.

W. Schmidt, G. Stingl, A. Schneeberger, 1999, Journal of immunology.

Role Defense Reaction : NK Cells Play a Major by the Magnitude and Quality of the Host DeterminedMurine M-3 D Melanoma Cells Is The Tumorigenicity of IL-2 Gene-Transfected

W. Schmidt, G. Stingl, A. Schneeberger, 1999 .

Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters.

K. Zatloukal, M. Cotten, E. Wagner, 1995, Journal of immunology.

Tumor vaccines and methods for their preparation

P. Steinlein, W. Schmidt, M. Buschle, 1995 .

In vivo production of human factor VII in mice after intrasplenic implantation of primary fibroblasts transfected by receptor-mediated, adenovirus-augmented gene delivery.

K. Zatloukal, M. Cotten, E. Wagner, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Tumor vaccines: effects and fate of IL-2 transfected murine melanoma cells in vivo.

K. Zatloukal, G. Maass, W. Schmidt, 1995, International journal of immunopharmacology.

Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study.

H. Kittler, H. Pehamberger, K. Wolff, 1999, Human gene therapy.

Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy

E. Masliah, E. Rockenstein, W. Schmidt, 2015, Molecular Neurodegeneration.

Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus

Johannes Söllner, Walter Schmidt, Duc Bui Minh, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Vaccination with poly-L-arginine as immunostimulant for peptide vaccines: induction of potent and long-lasting T-cell responses against cancer antigens.

W. Schmidt, M. Berger, M. Buschle, 2002, Cancer research.

Results from a Phase II Study to Assess the Clinical and Immunological Activity of AFFITOPE® AD02 in Patients with Early Alzheimer's Disease.

B. Dubois, J. Hort, A. Kurz, 2015, The journal of prevention of Alzheimer's disease.

Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination.

G. Maass, W. Schmidt, M. Berger, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Tailoring the Antibody Response to Aggregated Aß Using Novel Alzheimer-Vaccines

W. Schmidt, F. Mattner, D. Willbold, 2015, PloS one.

Development of Alzheimer AFFITOPE vaccines - from concept to clinical testing

W. Schmidt, F. Mattner, W. Zauner, 2009, Alzheimer's & Dementia.

Vaccination for Parkinson's disease.

W. Schmidt, F. Mattner, M. Mandler, 2012, Parkinsonism & related disorders.

Development of AFFITOPE vaccines for Alzheimer's disease

S. Kasper, W. Schmidt, P. Dal-Bianco, 2010, Alzheimer's & Dementia.

Genetic modification of cells by receptor-mediated adenovirus-augmented gene delivery: a new approach for immunotherapy of cancer.

K. Zatloukal, M. Cotten, E. Wagner, 1994, Verhandlungen der Deutschen Gesellschaft fur Pathologie.